Myeloid cell-based therapies in neurological disorders: How far have we come?

Chotima Böttcher, Josef Priller

Research output: Contribution to journalArticlepeer-review


The pathogenesis of neurological disorders such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) is multifactorial and incompletely understood. The development of therapies for these disorders of the central nervous system (CNS) is thus far very challenging. Neuroinflammation is one of the processes that contribute to the pathogenesis of CNS diseases, and therefore represents an important therapeutic target. Myeloid cells derived from the bone marrow are ideal candidates for cell therapy in the CNS as they are capable of targeting the brain and providing neuroprotective and anti-inflammatory effects. In this review, experimental and clinical evidence for the therapeutic potential of myeloid cells in neurological disorders will be discussed. This article is part of a Special Issue entitled: Neuro Inflammation edited by Helga E. de Vries and Markus Schwaninger.

Original languageEnglish
Pages (from-to)323-8
Number of pages6
JournalBBA - Bioenergetics
Issue number3
Early online date8 Oct 2015
Publication statusE-pub ahead of print - 8 Oct 2015


  • Journal Article


Dive into the research topics of 'Myeloid cell-based therapies in neurological disorders: How far have we come?'. Together they form a unique fingerprint.

Cite this